Related references
Note: Only part of the references are listed.The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant
Joseph R. Moskal et al.
CURRENT NEUROPHARMACOLOGY (2017)
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Brittany A. Jaso et al.
CURRENT NEUROPHARMACOLOGY (2017)
Potential serotonergic agents for the treatment of schizophrenia
Ricardo P. Garay et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Buprenorphine and the treatment of depression, anxiety, non-suicidal self-injury, and suicidality
L. Sher
ACTA PSYCHIATRICA SCANDINAVICA (2016)
Further Investigation of Ketamine
Robert Freedman
AMERICAN JOURNAL OF PSYCHIATRY (2016)
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
Jaskaran B. Singh et al.
AMERICAN JOURNAL OF PSYCHIATRY (2016)
Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial
Maurizio Fava et al.
AMERICAN JOURNAL OF PSYCHIATRY (2016)
Is Off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications
Melvyn W. Zhang et al.
BMC MEDICAL ETHICS (2016)
Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort
Raymond W. Lam et al.
BMC PSYCHIATRY (2016)
Associations of low grade inflammation and endothelial dysfunction with depression - The Maastricht Study
Fleur E. P. van Dooren et al.
BRAIN BEHAVIOR AND IMMUNITY (2016)
KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE
William V. Bobo et al.
DEPRESSION AND ANXIETY (2016)
Investigational drugs for treating agitation in persons with dementia
Ricardo P. Garay et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
Ricardo P. Garay et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study
Cheng-Ta Li et al.
HUMAN BRAIN MAPPING (2016)
Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain
Wayne A. Ray et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder
Suresh Durgam et al.
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Assessing the Risk Factors for Difficult-to-Treat Depression and Treatment-Resistant Depression
Bradley Gaynes
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study
Dawn F. Ionescu et al.
JOURNAL OF CLINICAL PSYCHIATRY (2016)
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Panos Zanos et al.
NATURE (2016)
The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence
James Lomas et al.
PHARMACOECONOMICS (2016)
Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Linda Nguyen et al.
PHARMACOLOGY & THERAPEUTICS (2016)
How to define treatment-resistant depression?
Jerome Holtzmann et al.
PRESSE MEDICALE (2016)
The roadmap for therapeutic strategies of treatment resistant depression
Wissam El-Hage
PRESSE MEDICALE (2016)
Resistant depression : other therapeutic strategies
Ghassen Saba et al.
PRESSE MEDICALE (2016)
Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
Yong-Ku Kim et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)
R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity
K. Hashimoto
PSYCHOLOGICAL MEDICINE (2016)
Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial
Debbie Tallon et al.
TRIALS (2016)
Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression
Amany K. Hassan et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2016)
Sudden Gains in Cognitive-Behavior Therapy for Treatment-Resistant Depression: Processes of Change
Anna Abel et al.
JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY (2016)
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris et al.
LANCET PSYCHIATRY (2016)
Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study
George I. Papakostas et al.
AMERICAN JOURNAL OF PSYCHIATRY (2015)
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression
D. Jeffrey Newport et al.
AMERICAN JOURNAL OF PSYCHIATRY (2015)
The promise of ketamine for treatment-resistant depression: current evidence and future directions
Kaitlin E. DeWilde et al.
AFFECTIVE DISORDERS AND TRAUMATIC BRAIN INJURY (2015)
Treatment-resistant Late-life Depression: Challenges and Perspectives
Christian Knoechel et al.
CURRENT NEUROPHARMACOLOGY (2015)
The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Leslie Citrome et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
L. Citrome
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2015)
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia A Randomized Clinical Trial
Jeffrey L. Cummings et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study
Michael E. Thase et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants
Michael E. Thase et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent
Sheldon Preskorn et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2015)
Is ketamine ready to be used clinically for the treatment of depression?
Colleen Loo
MEDICAL JOURNAL OF AUSTRALIA (2015)
Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial
Muhammad I. Husain et al.
TRIALS (2015)
Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization
Geng Tian et al.
SCIENTIFIC REPORTS (2015)
The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Leslie Citrome et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2015)
Evaluation of Opioid Modulation in Major Depressive Disorder
Elliot Ehrich et al.
NEUROPSYCHOPHARMACOLOGY (2015)
A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes
A. McGirr et al.
PSYCHOLOGICAL MEDICINE (2015)
Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist
Rachel Garner et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition
Panos Zanos et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
NMDA antagonists under investigation for the treatment of major depressive disorder
Bartlomiej Pochwat et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action
Marie Naughton et al.
JOURNAL OF AFFECTIVE DISORDERS (2014)
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
Roger S. McIntyre et al.
JOURNAL OF AFFECTIVE DISORDERS (2014)
A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression
J. Craig Nelson et al.
JOURNAL OF AFFECTIVE DISORDERS (2014)
C-reactive protein, interleukin-6, soluble tumor necrosis factor α receptor 2 and incident clinical depression
Patricia O. Chocano-Bedoya et al.
JOURNAL OF AFFECTIVE DISORDERS (2014)
Safety, Tolerability, and Clinical Effect of Low-Dose Buprenorphine for Treatment-Resistant Depression in Midlife and Older Adults
Jordan F. Karp et al.
JOURNAL OF CLINICAL PSYCHIATRY (2014)
Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration
Silvana Borges et al.
JOURNAL OF CLINICAL PSYCHIATRY (2014)
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects
G. Sanacora et al.
MOLECULAR PSYCHIATRY (2014)
Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder
Elizabeth Brunner et al.
NEUROPSYCHOPHARMACOLOGY (2014)
Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Linda Nguyen et al.
PLOS ONE (2014)
R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Ji-chun Zhang et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2014)
A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy
Jeremy D. Coplan et al.
FRONTIERS IN BEHAVIORAL NEUROSCIENCE (2014)
Association of Serum Interleukin 6 and C-Reactive Protein in Childhood With Depression and Psychosis in Young Adult Life A Population-Based Longitudinal Study
Golam M. Khandaker et al.
JAMA PSYCHIATRY (2014)
Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects A Systematic Review and Meta-analysis of Randomized Clinical Trials
Ole Kohler et al.
JAMA PSYCHIATRY (2014)
Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial
Olivia May Dean et al.
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2014)
Emerging antidepressants to treat major depressive disorder
Samantha G. Block et al.
ASIAN JOURNAL OF PSYCHIATRY (2014)
New paradigms for treatment-resistant depression
Carlos Zarate et al.
ANNALS REPORTS (2013)
A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression
Carlos A. Zarate et al.
BIOLOGICAL PSYCHIATRY (2013)
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
James W. Murrough et al.
BIOLOGICAL PSYCHIATRY (2013)
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Undine E. Lang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2013)
CRP, IL-6 and depression: A systematic review and meta-analysis of longitudinal studies
Vyara Valkanova et al.
JOURNAL OF AFFECTIVE DISORDERS (2013)
Effects of S-Ketamine as an Anesthetic Adjuvant to Propofol on Treatment Response to Electroconvulsive Therapy in Treatment-Resistant Depression: A Randomized Pilot Study
Kaija Jarventausta et al.
JOURNAL OF ECT (2013)
Daily Oral Ketamine for the Treatment of Depression and Anxiety in Patients Receiving Hospice Care: A 28-Day Open-Label Proof-of-Concept Trial
Scott A. Irwin et al.
JOURNAL OF PALLIATIVE MEDICINE (2013)
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht et al.
LANCET (2013)
Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature
A. J. Ferrari et al.
PSYCHOLOGICAL MEDICINE (2013)
Ketamine as a Novel Antidepressant: From Synapse to Behavior
J. W. Murrough
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Treatment-emergent adverse events associated with atypical antipsychotics
Danielle S. Cha et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder
Lobna Ibrahim et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2012)
Towards a glutamate hypothesis of depression An emerging frontier of neuropsychopharmacology for mood disorders
Gerard Sanacora et al.
NEUROPHARMACOLOGY (2012)
Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study
Tsuyoshi Miyaoka et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2012)
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Khalid Saad Al-Harbi
PATIENT PREFERENCE AND ADHERENCE (2012)
The drugs don't work? antidepressants and the current and future pharmacological management of depression
Elizabeth Penn et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2012)
Drug safety evaluation of ziprasidone
Leslie Citrome
EXPERT OPINION ON DRUG SAFETY (2011)
Treatment-Resistant Depression
Michael E. Thase
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents
Istvan Gyertyan et al.
NEUROCHEMISTRY INTERNATIONAL (2011)
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Adam L. Halberstadt et al.
NEUROPHARMACOLOGY (2011)
Stuck in a rut: rethinking depression and its treatment
Paul E. Holtzheimer et al.
TRENDS IN NEUROSCIENCES (2011)
Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ)
Gregory M. Chandler et al.
CNS NEUROSCIENCE & THERAPEUTICS (2010)
Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
Leslie Citrome
POSTGRADUATE MEDICINE (2010)
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Nanxin Li et al.
SCIENCE (2010)
The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments
Rodrigo Machado-Vieira et al.
PHARMACEUTICALS (2010)
σ-1 receptors in major depression and anxiety
Shrinivas K. Kulkarni et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2009)
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
Robert H. Howland
JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES (2009)
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder
Richard C. Shelton et al.
ACTA PSYCHIATRICA SCANDINAVICA (2008)
Glutamate and the neural basis of the subjective effects of ketamine
J. F. William Deakin et al.
ARCHIVES OF GENERAL PSYCHIATRY (2008)
Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders
Lewis L. Judd et al.
JOURNAL OF AFFECTIVE DISORDERS (2008)
Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors
Rena Cooper-Kazaz et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2008)
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report
A. John Rush et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
Carlos A. Zarate et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Determinants of trapping block of N-methyl-D-aspartate receptor channels
KV Bolshakov et al.
JOURNAL OF NEUROCHEMISTRY (2003)
NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D-2 and serotonin 5-HT2 receptors - implications for models of schizophrenia
S Kapur et al.
MOLECULAR PSYCHIATRY (2002)
Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile
AW Schmidt et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors:: Results from a placebo-controlled, randomized, double-blind, placebo wash-in study
BG Appelberg et al.
JOURNAL OF CLINICAL PSYCHIATRY (2001)
Share Paper
